



Aktualizovaná data k 5.5.2020

Cases reported by country*

Country	N
United States	321
Spain	168
France	76
Italy	59
United Kingdom	46
Iran, Islamic Republic of	46
Belgium	26
Germany	26
Switzerland	23
Netherlands	20
Brazil	17
Canada	16
Israel	16
Portugal	16
Austria	14

Cases reported by country*

Country	N
Missing	13
Ireland	8
Czech Republic	6
Turkey	6
Australia	4
Finland	4
Greece	3
India	3
Russian Federation	3
Norway	2
Qatar	2
United Arab Emirates	1
Bulgaria	1
Bahrain	1
Chile	1
China	1

Cases reported by country*

Country	N
Cyprus	1
Dominican Republic	1
Croatia	1
Hungary	1
Japan	1
Malaysia	1
New Zealand	1
Poland	1
Romania	1
Serbia	1

Showing 1 to 41 of 41 entries

* Countries not included in this table have not reported any cases to SECURE-IBD

Cases and outcomes by patient characteristics

Characteristic	Total N	Outpatient only (n, %)	Hospitalized (n, %)	ICU (n, %)	Ventilator (n, %)	Death (n, %)	ICU/Ventilator/Death (n, %)
Overall	959	637 66%	320 33%	62 6%	48 5%	37 4%	86 9%
Age							
0-9 years	3	3 100%	0 0%	0 0%	0 0%	0 0%	0 0%
10-19 years	33	30 91%	3 9%	0 0%	0 0%	0 0%	0 0%
20-29 years	181	147 81%	34 19%	2 1%	1 1%	0 0%	2 1%
30-39 years	197	154 78%	42 21%	7 4%	3 2%	2 1%	7 4%
40-49 years	183	128 70%	55 30%	10 5%	7 4%	2 1%	11 6%
50-59 years	151	91 60%	60 40%	10 7%	9 6%	3 2%	12 8%
60-69 years	114	52 46%	62 54%	23 20%	19 17%	12 11%	28 25%
70-79 years	53	17 32%	36 68%	8 15%	5 9%	6 11%	12 23%
>=80 years	40	12 30%	27 68%	1 3%	4 10%	11 28%	13 33%

Cases and outcomes by patient characteristics


Characteristic	Total N	Outpatient only (n, %)	Hospitalized (n, %)	ICU (n, %)	Ventilator (n, %)	Death (n, %)	ICU/Ventilator/Death (n, %)
Sex							
Male	502	313 62%	188 37%	34 7%	26 5%	27 5%	49 10%
Female	442	312 71%	129 29%	28 6%	22 5%	10 2%	37 8%
Other	#N/A	#N/A 0%	#N/A 0%	#N/A 0%	#N/A 0%	#N/A 0%	#N/A 0%
Disease type							
Crohn's disease	547	387 71%	159 29%	29 5%	24 4%	13 2%	36 7%
Ulcerative Colitis/unspecified	408	248 61%	160 39%	33 8%	24 6%	24 6%	50 12%

Cases and outcomes by patient characteristics

Characteristic	Total N	Outpatient only (n, %)	Hospitalized (n, %)	ICU (n, %)	Ventilator (n, %)	Death (n, %)	ICU/Ventilator/Death (n, %)
IBD Disease Activity							
Remission	571	403 71%	167 29%	33 6%	29 5%	21 4%	50 9%
Mild	173	124 72%	49 28%	6 3%	3 2%	7 4%	9 5%
Moderate/Severe	183	95 52%	87 48%	20 11%	15 8%	7 4%	24 13%
Unknown	32	15 47%	17 53%	3 9%	1 3%	2 6%	3 9%
Smoking							
Current smoker	44	20 45%	24 55%	3 7%	1 2%	4 9%	5 11%
Non-smoker	915	617 67%	296 32%	59 6%	47 5%	33 4%	81 9%

Cases and outcomes by patient characteristics

Characteristic	Total N	Outpatient only (n, %)	Hospitalized (n, %)	ICU (n, %)	Ventilator (n, %)	Death (n, %)	ICU/Ventilator/Death (n, %)
Comorbidities							
0	604	468 77%	135 22%	16 3%	11 2%	4 1%	19 3%
1	216	129 60%	86 40%	21 10%	14 6%	11 5%	26 12%
2	74	26 35%	48 65%	10 14%	12 16%	9 12%	17 23%
3+	65	14 22%	51 78%	15 23%	11 17%	13 20%	24 37%



Cases and outcomes by patient characteristics

Characteristic	Total N	Outpatient only (n, %)	Hospitalized (n, %)	ICU (n, %)	Ventilator (n, %)	Death (n, %)	ICU/Ventilator/Death (n, %)
IBD medication*							
Sulfasalazine/mesalamine	261	137 52%	124 48%	28 11%	28 11%	21 8%	44 17%
Budesonide	27	14 52%	13 48%	4 15%	3 11%	2 7%	4 15%
Oral/parenteral steroids	73	23 32%	49 67%	14 19%	10 14%	8 11%	18 25%
6MP/azathioprine monotherapy	95	58 61%	37 39%	7 7%	6 6%	2 2%	9 9%
Methotrexate monotherapy	6	3 50%	3 50%	0 0%	0 0%	0 0%	0 0%
Anti-TNF without 6MP/AZA/MTX	283	227 80%	55 19%	7 2%	3 1%	3 1%	8 3%
Anti-TNF + 6MP/AZA/MTX	93	58 62%	35 38%	10 11%	5 5%	2 2%	11 12%
Anti-integrin	88	61 69%	27 31%	4 5%	5 6%	2 2%	7 8%
IL 12/23 inhibitor	96	85 89%	11 11%	2 2%	1 1%	0 0%	2 2%
JAK inhibitor	16	11 69%	5 31%	2 13%	1 6%	1 6%	2 13%
Other IBD medication	36	20 56%	16 44%	3 8%	1 3%	1 3%	3 8%

*Medication categories are not mutually exclusive

Please use the following citation if referencing the data on this page: Brenner EJ, Ungaro RC, Colombel JF, Kappelman MD. SECURE-IBD Database Public Data Update. covidibd.org. Accessed on MM/DD/YY.

K.K. žena; 1976

- UC 2012 extenzivní tvar
- Terapie CS/AZA
- 2013 Infliximab
- 2015 Adalimumab
- 2016 Klinická studie Hickory – Etrolizumab ($\alpha 4\beta 7/\alpha E\beta 7$) anti-integrin
- 2018 Cottonwood remise nemoci (Etrolizumab 107 mg s.c 1 x měsíčně) ; intermitentně Cortiment 1x ob den
- 3.4.2019 totální koloskopie Mayo 0

K.K. nar. 1976

- Poslední aplikace studijní látky 3.3.2020
- Od poloviny března 2020 intermitentně krev ve stolici, tenesmy
- Od počátku dubna bolesti v podbřišku, zvýšené teploty únava, tenesmy cca 8-10 x denně
- Laboratoř 8.4.2020. CRP 195mg/l, leu 6.4; Hb 100g/l, hcz 31.7; trombo 399; lymfo 1.3;
- COVID-19 pozitivní PCR –RNA ze stěru
- Odmítla hospitalizaci na infekčním odd. v ČB
- Váha -3 kg (61kg)

K.K. žena;1976

- Léčena: Cortiment 9 mg 1x denně, Doxybene 100 mg 1x denně, lokálně : Budenofalk rektální pěna ráno + Asacol 4g klyzma večer
- Subj. trochu zlepšena, menší počet tenezmů (hlavně v noci), přetrvávají teploty, noční pocení poslední dva dny má kašel
- Dnes CT hrudníku v CB
- Krátkodobá hospitalizace 15.4-16.4.2020 vyloučeno postižení plic (rtg a CT)
- Dále v domácí karanténě

KK; žena nar. 1976

- Postupné a pomalé odeznívání respiračního infektu
- Od 20.4.2020 bez teplot a bez kašle
- 24.4. a 29.4. 2020 2x negativní SARS-CoV-2 RNA negativita
- 30.4.2020 kontrolní vyšetření sigmoidoskopické. Mayo 3 nejméně do 50ti cm
- Lab.: CRP 20.5mg/l, Hb 84g/l; Hct 0.29, Trombo 533x10⁹/l
- Terapie: Cortiment ex, Medrol tbl 48mg 5 dnů dnů, pak postupné snižování o 4 mg za týden, Pentasa ex, místo toho Sulfasalazin K-EN 3g denně, ATB ukončit